New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 29, 2014
06:31 EDTXLRNAcceleron Pharma price target raised to $65 from $35 at Piper Jaffray
Piper Jaffray raised its price target for Acceleron Pharma shares to $65 ahead of the clinical data read-outs it expects to start in June. Piper expects share value to be driven by the company's clinical progress for dalantercept, as it sees blockbuster potential in multiple cancers. The firm reiterates an Overweight rating on Acceleron.
News For XLRN From The Last 14 Days
Check below for free stories on XLRN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
16:44 EDTXLRNAcceleron, Celgene announce interim clinical data for sotatercept
Subscribe for More Information
April 22, 2014
07:23 EDTXLRNNational Kidney Foundation to hold a meeting
Subscribe for More Information
April 16, 2014
08:34 EDTXLRNPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use